Changes in treatment regimens have led to significant improvements in OS for children with tAML, and new opportunities on the horizon for additional forward movement. BCL-2, B-cell lymphoma 2; KMT2Ar, KMT2A rearrangement; R12/R17, registries 2012 and 2017.